KORU Medical Systems, Inc. Stock

Equities

KRMD

US7599101026

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 02:57:39 2024-04-24 pm EDT 5-day change 1st Jan Change
2.19 USD +2.34% Intraday chart for KORU Medical Systems, Inc. +4.72% -9.57%
Sales 2024 * 31.62M Sales 2025 * 38.72M Capitalization 99.67M
Net income 2024 * -6M Net income 2025 * -3M EV / Sales 2024 * 3.15 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.57 x
P/E ratio 2024 *
-15.6 x
P/E ratio 2025 *
-30.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.11%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : KORU Medical Systems, Inc., Q4 2023 Earnings Call, Mar 13, 2024
KORU Medical Systems, Inc. Enters into Loan and Security Agreement with HSBC Ventures USA Inc CI
KORU Medical Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
KORU Medical Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q4 Revenue $7.2M, vs. Street Est of $6.9M MT
KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024 CI
KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic CI
KORU Medical Systems, Inc. Signs Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for Novel Subcutaneous Immunoglobulin CI
Transcript : KORU Medical Systems, Inc. - Analyst/Investor Day
Transcript : KORU Medical Systems, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q3 Revenue $7M, vs. Street Est of $7.9M MT
KORU Medical Systems, Inc. Announces Development Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System CI
KORU Medical Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer CI
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes CI
More news
1 day+0.47%
1 week-0.47%
Current month-9.32%
1 month+1.90%
3 months+1.90%
6 months-10.46%
Current year-12.83%
More quotes
1 week
2.05
Extreme 2.05
2.22
1 month
2.05
Extreme 2.05
2.71
Current year
1.98
Extreme 1.9783
2.71
1 year
1.98
Extreme 1.9783
4.48
3 years
1.82
Extreme 1.82
4.83
5 years
1.49
Extreme 1.49
12.84
10 years
0.16
Extreme 0.156
12.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 21-04-11
Director of Finance/CFO 52 21-10-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 69 21-12-31
Chairman 78 19-05-06
Director/Board Member 64 23-09-27
More insiders
Date Price Change Volume
24-04-24 2.21 +3.27% 30 140
24-04-23 2.14 +0.47% 84,146
24-04-22 2.13 +2.40% 72,513
24-04-19 2.08 +0.97% 59,143
24-04-18 2.06 -2.83% 61,319

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes
KORU Medical Systems, Inc. designs, manufactures, and markets proprietary portable and advanced medical devices primarily for the subcutaneous drug delivery market. It is focused on home and specialty infusion solutions. The Company's focus is primarily concentrated on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. The devices are used for infusions administered at home and in alternate care settings. Its infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient's subcutaneous tissues can tolerate and what the system delivers.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.14 USD
Average target price
3.375 USD
Spread / Average Target
+57.71%
Consensus